Farther Finance Advisors
LRMR icon

Farther Finance Advisors’s Larimar Therapeutics LRMR Stock Holding History

Farther Finance Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.8K Buy
4,631
+764
+20% +$2.95K ﹤0.01% 4378
2026
Q2 		$11.8K Buy
3,867
+761
+25% +$3.02K ﹤0.01% 4314
2026
Q1 		$14.5K Buy
3,106
+106
+4% +$424 ﹤0.01% 3869
2025
Q4 		$11.4K Hold
3,000
– – ﹤0.01% 3823
2025
Q3 		$9.69K Hold
3,000
– – ﹤0.01% 3459
2025
Q2 		$8.67K Buy
+3,000
New +$6.95K ﹤0.01% 3143

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors's LRMR Position: Q3 2026 in Review

Farther Finance Advisors increased its Larimar Therapeutics (LRMR) stake by 20% in Q3 2026, buying an estimated $2.95K and bringing the position to 4,631 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

Farther Finance Advisors first reported a position in LRMR in Q2 2025 and has held it in 6 quarters since. 7 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Farther Finance Advisors held 4,631 shares of Larimar Therapeutics worth $14.8K as of Q3 2026.
  • Farther Finance Advisors bought 764 Larimar Therapeutics shares in Q3 2026, an estimated $2.95K.
  • Larimar Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4378 holding.
  • Farther Finance Advisors first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 7 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.